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http://www.tobaccoinduceddiseases.com/content/11/1/10RESEARCH Open AccessCigarette smoke extract induces differential
expression levels of beta-defensin peptides
in human alveolar epithelial cells
Tony Pierson1, Sarah Learmonth-Pierson1, Daniel Pinto1 and Monique L van Hoek1,2,3*Abstract
Background: The damaging effects of cigarette smoke on the lungs are well known in terms of cancer risks.
Additional molecular changes within the lung tissue can also occur as a result of exposure to cigarette smoke. The
human β-defensin (hBD) class of antimicrobial peptides is the focus of our research. In addition to antimicrobial
activity, β-defensins also have immunomodulatory functions. Over 30 previously unrecognized β-defensin genes
have recently been identified in the human genome, many with yet to be determined functions. We postulated
that altered β-defensin production may play a role in the pathogenesis observed in the lungs of smokers. Our
hypothesis is that cigarette smoke exposure will affect the expression of β-defensins in human lung alveolar
epithelial cells (A549).
Methods: We exposed A549 cells to cigarette smoke extract (CSE) and measured the changes in mRNA levels of
several antimicrobial peptides by quantitative real-time PCR, and directly observed peptide expression in cells by
immunofluorescence (IF) microscopy.
Results: We found that hBD3, hBD5, and hBD9 gene expression was upregulated in A549 cells exposed to CSE.
HBD1, hBD8, hBD18 and LL-37 gene expression did not significantly change upon exposure to CSE. Expression of
hBD3 and hBD4 peptides was visualized by IF.
Conclusions: This differential expression suggests that hBD3, hBD5, and hBD9 may play a role in the changes
to the lung tissue observed in smokers. Establishing differential β-defensin expression following CSE treatment
will add to our understanding of the molecular response of the lung alveolar epithelium to cigarette smoke
exposure.
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Smoking cigarettes increases the risk of contracting lung
cancer [1]. Lung cancer caused an estimated 159,300
deaths in the United States in 2009, and is the leading
cause of cancer related mortality [2]. In addition to causing
cancer, smoking increases the risk of dying prematurely
due to chronic obstructive pulmonary disease (COPD) or
emphysema [3], stroke and cardiac arrest [4]. Cigarette
smoke contains thousands of chemical components, many
of which are capable of acting as either carcinogens [5] or* Correspondence: mvanhoek@gmu.edu
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reproduction in any medium, provided the orforeign antigens [6-8]. Once inhaled, some cigarette smoke
components adhere to cells lining the respiratory tract,
triggering a robust response by lung cells, including
activating the innate immune system [9].
Antimicrobial Peptides (AMPs) are small (<100 amino
acids) peptides that play a critical role in host airway
defense as part of the innate immune system [10]. α and β
are the two major classes of defensin AMPs. β-defensin
expression is associated with some chronic lung diseases,
including COPD [11-14]. In addition to α and β defensins,
humans possess one member of the cathelicidin class
of AMP, LL-37, which was also assessed in these
experiments. α-defensins are not expressed in epithelial
cells, and were not measured in the present study.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is a model system used to model alveolar epithelial type
II cells (ATII). We used this model for the quantification
of relative AMP expression levels after exposure to bacteria
[15]. Although this model has been extensively used in the
literature, the limitation of this model is that it does not
undergo differentiation to express the alveolar type I (ATI)
phenotype [16]. Given the specific goal of this experiment,
we determined that the A549 model was an appropriate
tool for our study. In this experiment we tested mRNA
level changes in response to exposure to cigarette-smoke
extract (CSE) of known as well as recently identified
β-defensin genes [17-20].
Until recently, only four human β-defensins (hBDs)
were known to be expressed in respiratory epithelial
cells (hBD1, hBD2, hBD3 and hBD4) [21-23]. However,
recent computational and genomic research has predicted
over 30 additional human β-defensins, many of which
have not been investigated for their biological function
[17,24]. Importantly, defensin peptides appear to play
multiple roles in vivo and exhibit an immunomodulatory
function, similar to cytokines or chemokines. Expression
of β-defensins can be induced via NF-κB activation mainly
through TLR receptor binding to microbial components,
or via pro-inflammatory cytokines, such as TNF-α and
IL1-β. Weinberg characterized β-defensins as complex
molecules whose proper function is critical for effective
immune system function and that when β-defensin
production is altered, especially in areas where cells
are already not functioning properly, AMP expression
may actually increase disease progression [25]. In
addition to the pathological changes observed in lungs
exposed to smoke, exposed bronchial epithelial cells
secrete many cytokines with the ability to stimulate
immune cell migration [26]. β-defensin expression may
also produce a cellular environment where inflammation is
enhanced [25] and vascular permeability is increased [27].
Recent publications have shown that exposure of
cells to cigarette smoke represses the induction of hBD2
expression by cells exposed to the bacterial lipopolysac-
charide [28,29]. Human gingival epithelial cells exposed to
cigarette smoke show increased expression of several
β-defensins as well as proinflammatory cytokines [30].
Cigarette smoke directly or indirectly alters the expression
of hBD2 [31]. It has also been suggested that this peptide
may play a role in the pathogenic effects caused by
cigarette smoke [20]. Our hypothesis is that exposure of
Human Alveolar Epithelial Cells (A549) to cigarette
smoke will lead to measurable changes in gene expression
levels for some of the newly-identified human β-defensin
peptides (hBDs) as measured by quantitative real-time
PCR (qRT-PCR). Our finding that exposure to cigarette
smoke increases certain β-defensin gene expression would
suggest that repeated exposure with each new cigarettewould lead to chronic over-expression of those β-defensins
and possibly exacerbate the deleterious effects of cigarette
smoke-damaged cells.
Materials and methods
β-defensin Induction in A549 cells
Low passage human lung epithelial cell line (A549,
ATCC CCL-185) were grown to 95% confluence in 6
well culture plates (1 × 106 cells per well, BD catalog #
353046) with Ham’s F-12 (Cellgro 10-080-CV)
containing 10% heat inactivated fetal bovine serum, 37°C,
5% CO2. Cells were then washed with PBS and fed
serum-free Hams F-12 media overnight. Following the
previously established protocol [5,31], cells were exposed
to either 50 μg/ml of the 40 mg/ml stock solution of
cigarette smoke extract (CSE in 100% DMSO) in Ham’s
F-12 media, or an equivalent amount of DMSO alone in
Ham’s F-12 media, or 10 ng/ml of IL-1β (Sigma) in
Ham’s F-12 media, for 30 minutes.
Cigarette Smoke Extract (CSE)/Cigarette smoke
condensate (CSC)
CSE was purchased from Murty Pharmaceuticals, Lexington
KY [5,31]. According to the manufacturer CSE was
produced by burning one University of Kentucky
“1R13” cigarette and extracting the total particulate
into 100% DMSO to prepare a 40 mg/ml stock solution.
Cells were exposed to 50 μg/ml of the 40 mg/ml stock
solution of cigarette smoke extract (CSE in 100% DMSO)
suspended in Ham’s F-12 media. The control cells
received the equivalent volume of DMSO devoid of CSE
suspended in Ham’s F-12 media. Previously published
reports using this material were followed [5,31].
Analysis of AMP gene expression by quantitative reverse
transcription qRT-PCR
After exposure, cells were harvested, mRNA, extracted,
and cDNA made following our previously published
protocol for qRT-PCR of antimicrobial peptides [15,32].
Quantitative RT-PCR was performed with primers specific
for the following β-defensin peptides: hBD1, hBD3, hBD5,
hBD6, hBD8, hBD9, hBD18, and the cathelicidin LL-37 in
order to measure how much each gene was activated or
inhibited by the cigarette smoke treatment. Control cells
were used as a baseline to compare induction of gene
expression in cells exposed to cigarette smoke extract, and
levels of 18S rRNA were used to normalize between
samples, leading to the relative units of expression indicated
for each experiment. Using a previously established
protocol [15,32], quantitative real-time PCR analysis in
a MyiQ Single Color Real-Time PCR Detection System
(BioRad Laboratories) was performed according to the
manufacturer’s instructions. Primer sequences and melting
temperatures are summarized in Table 1.
Table 1 Quantitative RT-PCR primer sequences used in this study
Primers Sequences Melting temp Product size Reference
HBD1 Forward 5′-CCCAGTTCCTGAAATCCTGA-3′ 56°C 215bp (Han et al., 2008) [15]
Reverse 5′-CAGGTGCCTTGAATTTTGGT-3′ 56°C
HBD3 Forward 5′-AGCCTAGCAGCTATGAGGATC-3′ 56°C 206bp (Han et al., 2008) [15]
Reverse 5′-CTTCGGCAGCATTTTGCGCCA-3′
HBD5 Forward 5′-TCCATCAGGTGAGTTTGCTG-3′ 57°C 105bp (*)
Reverse 5′-GTTCAGCCTGCAATTTCCAT-3′
HBD8 Forward 5′-TGCCTTGAAACAGAAATCCA-3′ 56°C 104bp (**)
Reverse 5′-TCCTTTTTGGGTGTAGTGCTC -3′
HBD9 Forward 5′-GGCCTAAATCCAGGTGTGAA-3′ 57°C 174bp (Alekseeva et al., 2009) [33]
Reverse 5′-TCAAATGTTGGCAAGTGGAG-3′
HBD18 Forward 5'-TGCATTCCATCCAATGAAGA-3′ 57°C 181bp (***)
Reverse 5′-GAGGTCTCAGTTCCCCTTCC-3′
LL-37 Forward 5′-CTAGAGGGAGGCAGACATGG-3′ 57°C 201bp (Amer, Bishop, & van Hoek, 2010) [32]
Reverse 5′-AGGAGGCGGTAAGGTTAGC-3′
This table summarizes the primers that were used in this study, the melting temperature, the predicted product size and relevant references. Invitrogen
OligoPerfect™ Designer was used to design new primers. (*) NM_152250.1 Homo sapiens defensin, beta 105A (DEFB105A), mRNA; (**) NM_001002035.1 Homo
sapiens defensin, beta 108B (DEFB108B), mRNA; (***) NM_054112.2 Homo sapiens defensin, beta 118 (DEFB118), mRNA.
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A549 cells were grown on chambered slides (BD Falcon,
354108) and exposed to CSE as above for β-defensin
induction. Cells were fixed, permeabilized and blocked
as previously described [34], and a 1:500 dilution of
anti-human β-defensin primary antibody (Abcam, ab14421
Anti-beta Defensin 1 antibody, ab19270 Anti-beta 3
Defensin antibody, ab70215 Anti-beta 4 Defensin antibody)
was applied for 1 hr. Detection was performed with 1:5000
dilution of secondary antibody labeled with Alexafluor
488 (Green), using ProLong Gold anti-fade with DAPI
(Blue). Images were obtained as previously described [34],
using the Nikon Confocal microscope.
Statistical analysis
Statistical analysis and graphing was carried out using
Prism 5 software (GraphPad, La Jolla, CA). The two-tailed
t-test assuming unequal variance was used to compare
negative control β-defensin gene expression of the two
different experimental groups expression profiles (IL-1β,
cigarette smoke extract, CSE) compared to the control
(DMSO alone).
Ethical & safety approvals
All experiments were approved by the Institutional Review
Board at George Mason University. Since only a commer-
cially available, de-identified human cell line was used, no
ethical approvals were required for this research.
Results
Based on emerging reports of potentially important roles
for some of the newly discovered human β-defensinsin lung defense (hBD3, hBD5, hBD8, hBD9, hBD18)
[18,24,33], and the emerging role of hBD1 in COPD [11],
we chose to study this selected set of the human β-defensin
genes that had not been previously examined for their
alteration following exposure to cigarette smoke (CSE)
[29,35]. We included the human cathelicidin, LL-37/CAMP,
as a comparator, as it also is thought to play a significant
role in lung defense [17].
HBD1
The first identified human β-defensin gene, hBD1, is
considered a constitutively produced antimicrobial peptide,
whose expression has not been observed to change
significantly under physiological conditions [36,37].
Following treatment with 50 μg/ml cigarette smoke
(CSE), there is no significant change in hBD1 expression
(Control = 1.000+/−0.324, CSE = 0.643+/−0.046, p > 0.05)
compared to mock treated cells. This confirms previous
findings, as the expression of this peptide is also not
up-regulated by 10 ng/ml of IL-1β treatment (IL-1β =
1.123+/−0.086) (n = 3) compared to mock treated
cells (Figure 1A).
HBD3, hBD5 and hBD9
The human β-defensins hBD3, hBD5 and hBD9 were
found to be significantly increased following treatment
with 50 μg/ml cigarette smoke extract (CSE) when
compared to mock treated cells, and induced as much as
with 10 ng/ml of IL-1β treatment. In response to CSE,
hBD3 was 7.95 fold increased (p = 0.032), hBD5 was 2.8 fold
increased (p = 0.0083) and hBD9 was 4.2 fold increased
(p = 0.0078). (n = 3 for hBD3, 9, n = 6 for hBD5) (Figure 1B).
Figure 1 Expression of Antimicrobial peptides A. Expression of hBD1. The constitutively expressed β-defensin, hBD1, is not induced by IL-1β
treatment, as measured by qRT-PCR (Control = 1.000+/−0.324, IL-1β =1.123+/−0.086) (n = 3). Although the means differ, the treatment by
cigarette smoke extract (CSE) did not statistically significantly alter the level of hBD1 expression as measured by T-test (Control = 1.000+/−0.324,
CS = 0.643+/−0.046, p > 0.05). B. Expression of hBD3, hBD5, and hBD9. Cigarette Smoke Extract (CSE) induces the expression of hBD3, hBD5 and hBD9.
Following treatment with CSE the expression of hBD3, hBD5 and hBD9 were all significantly (p < 0.05) induced as measured by qRT-PCR to levels
similar to those achieved with IL-1β treatment. (hBD3 was 7.95 fold increased (p = 0.032), hBD5 was 2.8 fold increased (p = 0.0083) and hBD9 was 4.2
fold increased (p = 0.0078). n = 3 for hBD3, 9, n = 6 for hBD5). C. Expression of hBD 8, hBD18 and LL-37. Cigarette Smoke Extract (CSE) does NOT induce
expression of hBD8, hBD18, LL-37. Measured by qRT-PCR, the expression of hBD8 and LL-37 is not significantly induced in response to cigarette smoke
extract (p > 0.05), however these defensins are significantly (p < 0.05) induced by IL-1β treatment. HBD18 was also not statistically significantly induced
with cigarette smoke extract, although the means differed (Control = 1.000+/−0.287, CSE = 3.207+/−1.862, p = 0.31)(n = 3).
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Expression of the antimicrobial peptide gene hBD8 was
not significantly induced in response to 50 μg/ml cigarette
smoke extract (CSE) (p > 0.05), however this β-defensin is
significantly (p < 0.05) induced by 10 ng/ml of IL-1βtreatment. The expression of another β-defensin peptide
gene hBD18 was not statistically significantly induced with
50 μg/ml cigarette smoke extract, although the means
differed (Control = 1.000+/−0.287, CSE = 3.207+/−1.862)
(p = 0.31). (Figure 1C).
A. B.
Figure 2 Immunofluorescence Microscopy of hBDs in A549 cells treated with cigarette smoke extract. Green = human β-defensin
(Alexafluor 488), Blue = nuclei (DAPI). A. hBD3 protein is observed in punctate staining in A549 cells (White arrow points to punctate staining).
B. hBD4 protein is observed in heavily punctate staining in A549 cells (White arrow points to punctate staining).
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Expression of the cathelicidin gene LL-37 was not signifi-
cantly induced in response to 50 μg/ml cigarette smoke
extract (CSE) (p > 0.05) either, however this antimicrobial
peptide gene is significantly (p < 0.05) induced by 10 ng/ml
of IL-1β treatment. (Figure 1C).
Visualization of hBDs by fluorescent microscopy
A549 cells exposed to 50 μg/ml cigarette smoke (CSE)
and processed in situ displayed positive staining for
the internal presence of human β-defensins (Figure 2).
Immunofluorescent microscopy was performed of cigarette-
smoke treated A549 cells staining for hBD1, hBD3, and
hBD4. Shown are representative images of staining for
hBD3 and hBD4 peptides. No differential defensin staining
was observed in the cells for hBD1 (data not shown),
suggesting a similar result as was shown by the lack of
induction of hBD1 seen in the qRT-PCR study.
Discussion
A549 cells are considered to be a cell-line model for
Type II alveolar epithelial cells, which secrete the lung
surfactant and A549 express some of the markers of
Type II cells [38,39]. In this study, we use the A549 cell
model to measure relative gene expression of two classes
of AMP; human β-defensins (hBDs) and the human
cathelicidin (LL-37) in response to exposure to cigarette
smoke extract. Total RNA was extracted from the samples
and quantitative real-time PCR was performed to quantify
AMP gene expression using gene specific primers.
The experimental approach was to expose A549 cells
to 50 μg/ml cigarette smoke extract (dissolved in
DMSO), compared to control cells treated with DMSO
alone. The positive control cells were exposed to 10 ng/mlIL-1β which is known to up-regulate the expression of
many defensin peptides [33]. The mRNA was then
prepared from all samples, and qRT-PCR was performed
for hBD1, hBD3, hBD5, hBD8, hBD9, hBd18, and the
Cathelicidin LL-37. Overall, the application of 10 ng/ml
IL-1β to A549 cells induced the expression of most of the
tested human β-defensins (except hBD1, see below),
confirming that the cells responded to the stimuli as
expected.
We found that hBD3, hBD5, and hBD9 gene expression
was up-regulated in A549 cells exposed to 50 μg/ml CSE,
while hBD1, hBD8, hBD18 and LL-37 gene expression did
not significantly change. Expression of hBD1, hBD3
and hBD4 peptides within the A549 cells (in situ) was
visualized by IF. This differential expression suggests
that hBD3, hBD5, and hBD9 may play a role in the changes
to the lung tissue observed in smokers. Establishing the
differential human β-defensin gene expression following
CSE treatment will add to our understanding of the
molecular response of the lung alveolar epithelium to
cigarette smoke exposure.
Our data demonstrates the differential induction of
expression of specific β-defensin peptide genes as a
result of exposure to cigarette smoke extract and suggests
that three β-defensin genes (hBD3, hBD5, hBD9) may
represent biomarkers of cigarette smoke extract exposure
for alveolar epithelial cells [40-46]. These findings may
contribute to a greater understanding of the role of the
newly identified β-defensin peptides in the response of
lung epithelial cells to cigarette-smoke. Further studies of
other sample types from smokers, such as bronchoalveolar
lavage could be used to validate these findings. Such
biomarkers may have utility in studying the recovery of
lung cells following the cessation of smoking.
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to cigarette smoke or IL-1β, as expected. The expression
of hBD5, hBD8, hBD9 and hBD18, four of the new
members of the human β-defensin gene family, are
inducible by IL-1β in A549 lung epithelial cells, indicating
they may respond to IL-1β regulation in vivo and may be
involved in inflammatory responses and cell proliferation,
differentiation, and apoptosis. Three genes, hBD8, hBD18
and the cathelicidin LL-37, were induced with IL-1β
treatment, but not with cigarette smoke treatment,
suggesting there is specificity of regulation for the different
β-defensins. hBD3, hBD5, and hBD9 gene expression was
increased by cigarette smoke extract treatment to the
same extent as with IL-1β treatment. This suggests that
these three β-defensins may have similar regulation by
components of the cigarette smoke extract. Similarly,
differentially-regulated expression of hBD3 and hBD9 was
observed in infectious keratitis of the human eye [47]
supporting that differential regulation of human β-defensin
gene expression can occur. HBD3 is thought to be an
important component of lung defense, such as in response
to Legionella infection [48].
Exposure to cigarette smoke is thought to be harmful
to host respiratory defenses through multiple modes of
action [8]. Recent studies have suggested that cigarette
smoke alters the production of hBD2 [28,29,49-54]. The
induction of hBD2 and hBD3 expression (as well as IL-1B)
in human gingival epithelial cells by cigarette smoke is
thought to be through the activation of ERK1/2 and NF-kB
pathways [30]. Nictotine has been reported to upregulate
the expression of hBD2 via a p38 MAPK dependent
pathway in human keratinocytes [55]. Cigarette smoke
contains many toxic components, including potentially
bacterial lipopolysaccharides [56], which in combination
with the delivered nicotine could contribute to these
observed effects of cigarette smoke. HBD2 is expressed
in keratinocytes, the gingival mucosa and the tracheal
epithelium [48,57-59] and alteration of its gene expression
has been found in many diseases, such as infectious
diseases, CF, and lupus erythematosus [60].
Xu recently showed that cigarette smoke extract
significantly increased the production of IL-1β [57]. It
was also shown that cigarette smoke inhibits the sub-
sequent induction of hBD2 expression in response to
bacterial lipopolysaccharide [52] or IL-1β [51], suggesting
that cigarette smoke also may suppress the normal host
defense response to bacterial pathogen exposure in the
lung [35]. Kanda et al. recently demonstrated that exposure
to hBD2 enhanced mRNA levels and secretion of many
cytokines, including IL-1β [58]. Therefore, cigarette smoke
may directly stimulate novel hBD production, leading to
enhancement of IL-1β, which in turn could further
stimulate additional hBD production, in a paracrine or
autocrine loop. Interestingly, Kanda also reported thatthe effects of hBD2 were counteracted by the drug
Pentoxifylline (PTX) [58]. PTX is a drug with strong
anti-inflammatory properties. This observation suggests
that we should investigate the ability of PTX to potentially
counteract the effect of chronic CSE-induced over-
expression of human β-defensins.
Stimulation of oral squamous cell carcinoma (BHY-
OSCC) cell line with hBD1 results in reduction of cell
proliferation, whereas hBD2 and hBD3 stimulation causes
promotion of cell proliferation, indicating that hBD2 and
hBD3 might be protooncogenes in OSCCs [59]. Recent
studies demonstrated all lung tumor samples, independent
of their histological type, express hBD2 peptide, and its
expression levels correlates with the differentiation grade
of lung adenocarcinoma [61], suggesting that the role
of human β-defensins in lung cancer should be further
investigated also.
The health effects of cigarette smoke on lung health
are significant. Establishing a link between smoking and
the induction of novel and established antimicrobial
peptides is an important step in understanding the
pathology observed in cigarette smokers. AMPs may
represent novel biomarkers of overall lung cell health
status, as well as having potential direct effects in the
pathogenesis of cigarette smoking. In the long term, we
would like to investigate whether chronic antimicrobial
peptide induction may contribute to lung pathology,
which may occur before the occurrence of cancer or
Chronic Obstructive Pulmonary Disease (COPD). If so,
AMP induction could potentially be useful as both a
biomarker of cigarette exposure, as well as a possible
target for therapeutic intervention.
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